Dual pathway antithrombotic treatment and risk reduction in patients with atherosclerotic cardiovascular disease - a real-world perspective

The persisting risk of cardiovascular disease (CVD) events despite reaching targets for known CVD risk factor such as low density lipoprotein (LDL) cholesterol, blood pressure, glycemia, and body weight is summarized as residual CVD risk. Conditions that may contribute to a residual CVD risk include inflammation, pro-thrombotic imbalance of the coagulation system, and metabolic pathways. These risk modifiers that are usually underrecognized and not addressed in clinical practice may contribute to recurrent cardiovascular events.
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research